Why the study?
Does the addition of high-dose extended-release niacin to statin therapy affect the safety profile or provide clinical benefit in patients with stable atherosclerotic disease, low HDL, and elevated triglycerides?
Does the addition of high-dose extended-release niacin to statin therapy affect the safety profile or provide clinical benefit in patients with stable atherosclerotic disease, low HDL, and elevated triglycerides?
Answers are grounded in this paper and cite their sources.
The addition of high-dose extended-release niacin to statin therapy provides no incremental clinical benefit in patients with stable atherosclerotic disease and atherogenic dyslipidemia.
To the Editor: The results of the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial were published in the Journal in 2011.1 This study showed no incremental clinical benefit from the addition of high-dose extended-release niacin (Niaspan, AbbVie) to statin therapy during a 36-month mean follow-up period in 3414 patients who had stable atherosclerotic disease, low baseline levels of high-density lipoprotein (HDL) cholesterol, and elevated triglyceride levels. In that article, we provided data on adverse events resulting in a reduction in the dose or discontinuation of the study drug. These results were . . .
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: